<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745794</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0519</org_study_id>
    <secondary_id>NCI-2018-02182</secondary_id>
    <secondary_id>2018-0519</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03745794</nct_id>
  </id_info>
  <brief_title>Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery</brief_title>
  <official_title>Randomized Controlled Trial of Repeat vs. Single Quadratus Lumborum Block to Reduce Opioid Prescriptions After Open Pancreatectomy (&quot;RESQU-BLOCK&quot; Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how an additional anesthetic nerve block, called a quadratus
      lumborum block, works to reduce the need for opioids in patients after pancreatic surgery.
      Giving an additional regional anesthetic after surgery may hasten the weaning process, reduce
      the need for opioid medications upon discharge, and reduce the risk of opioid dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To use a phase II randomized controlled trial to compare the intervention of a second
      regional anesthetic block (quadratus lumborum [QL] block) versus usual care (single
      intraoperative QL block) to increase the proportion of opioid-free pancreatic cancer
      survivors at discharge after potentially curative surgery.

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM 1: Patients undergo QL block before surgery and receive standard of care multimodal pain
      control after surgery.

      ARM 2: Patients undergo QL block before surgery and receive multimodal pain control. Patients
      then undergo a second QL block on day 4 after surgery and continue to receive standard of
      care.

      After completion of study treatment, patients are followed up at 1 month, 3 months, 6 months,
      and 1 year after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of opioid-free patients between the two arms</measure>
    <time_frame>At discharge date, Up to post-op day 30</time_frame>
    <description>Will perform Chi-squared test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total inpatient oral morphine equivalents (OME)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital cost</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Two sample t-test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score assessed by MD Anderson Symptom Inventory-Gastrointestinal (MDASI-GI)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain prescription dosage/size</measure>
    <time_frame>At discharge date, Up to post-op day 30</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with initial discharge prescription dosage/size total OME &lt; 200 mg</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients using opioids</measure>
    <time_frame>At 30 days after surgery</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDASI-GI in clinic visits</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients using opioids</measure>
    <time_frame>At 90 days after surgery</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total OME for first 30 days and first 90 days (inpatient + outpatient)</measure>
    <time_frame>At 30 and 90 days</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients and family free of opioid use</measure>
    <time_frame>At 6 months and 1 year</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (QL block, standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo QL block before surgery and receive standard of care multimodal pain control after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (second QL block)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo QL block before surgery and receive multimodal pain control. Patients then undergo a second QL block on day 4 after surgery and continue to receive standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Given standard of care</description>
    <arm_group_label>Arm I (QL block, standard of care)</arm_group_label>
    <arm_group_label>Arm II (second QL block)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quadratus Lumborum Block</intervention_name>
    <description>Undergo QL block</description>
    <arm_group_label>Arm I (QL block, standard of care)</arm_group_label>
    <arm_group_label>Arm II (second QL block)</arm_group_label>
    <other_name>QL Block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (QL block, standard of care)</arm_group_label>
    <arm_group_label>Arm II (second QL block)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (QL block, standard of care)</arm_group_label>
    <arm_group_label>Arm II (second QL block)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients undergoing elective open pancreatic resection for potentially curative
             intent (pancreaticoduodenectomy or distal pancreatectomy) who would otherwise be
             treated with QL block + IV-PCA converted to oral pain meds (non-narcotic bundle +
             opioid pain pill).

        Exclusion Criteria:

          -  Patients with current or past substance (drug or alcohol) abuse disorder.

          -  Laparoscopic or minimally invasive surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ching-Wei D Tzeng</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ching-Wei D Tzeng</last_name>
    <phone>713-792-6940</phone>
    <email>cdtzeng@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Wei D. Tzeng</last_name>
      <phone>713-792-6940</phone>
    </contact>
    <investigator>
      <last_name>Ching-Wei D. Tzeng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

